A patented AI workflow that segments pediatric ocular globes from axial head CT, normalizes orientation, and applies deep learning to estimate retinal hemorrhage likelihood per eye, using CT data already acquired. UTRF is offering an exclusive or non-exclusive license to an imaging-AI platform, CT OEM, or enterprise-imaging company.
Retinal hemorrhage is clinically important in evaluating possible abusive head trauma, but it's rarely identified on routine CT interpretation — the reference standard, dilated ophthalmologic exam, isn't always accessible. Head-CT AI is already crowded for intracranial hemorrhage, leaving this specific finding undetected on a scan already being acquired. And even a strong algorithm stays commercially inert without DICOM/PACS/EHR integration, AI governance, and a regulated deployment pathway — infrastructure no single academic team builds alone.
A patented AI workflow (U.S. Patent App. 18/421,718, Notice of Allowance received) that segments pediatric ocular globes from axial head CT, normalizes orientation, and applies deep learning to estimate retinal hemorrhage likelihood per eye — using CT data already acquired, no additional imaging required. UTRF is offering an exclusive or non-exclusive license to an imaging-AI platform, CT OEM, or enterprise-imaging company to pair this algorithm with existing infrastructure and carry it through reproducibility confirmation, multi-site validation, workflow definition, engineering, and regulatory strategy.
Patent Pending
UT offers a partnership model that reduces risk, accelerates time-to-value, and supports long-term growth strategies for industry—providing an attractive platform for companies seeking to formalize collaboration and establish a long-term presence in the East Tennessee region. By aligning institutional investment with regional and national priorities, UT provides a stable and effective platform for industry collaboration, technology deployment, and sustained economic impact.